Sunday, March 29, 2020 10:27:11 AM
Research facilities named in BC COVID-19 battle
"While some patients have been undergoing the experimental treatment, the bulk of the research in B.C. has been taking place inside labs at the University of British Columbia and the B.C. Centre for Disease Control, Henry said".
https://www.cbc.ca/news/canada/british-columbia/malariaa-medication-covid-1.5513899
Hopefully Lexaria is involved as per their news releases in my last post.
In the CBC article, the Anti-viral Remdesivir is mentioned as being a drug being tested in BC. Here's another article talking about Remdesivir.
https://www.drugtargetreview.com/news/58608/remdesivir-most-promising-covid-19-drug-say-researchers/
"While some patients have been undergoing the experimental treatment, the bulk of the research in B.C. has been taking place inside labs at the University of British Columbia and the B.C. Centre for Disease Control, Henry said".
https://www.cbc.ca/news/canada/british-columbia/malariaa-medication-covid-1.5513899
Hopefully Lexaria is involved as per their news releases in my last post.
In the CBC article, the Anti-viral Remdesivir is mentioned as being a drug being tested in BC. Here's another article talking about Remdesivir.
https://www.drugtargetreview.com/news/58608/remdesivir-most-promising-covid-19-drug-say-researchers/
Recent LEXX News
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications • ACCESS Newswire • 05/01/2026 01:25:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 04/29/2026 01:10:00 PM
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs • ACCESS Newswire • 04/23/2026 01:05:00 PM
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales • ACCESS Newswire • 04/21/2026 01:10:00 PM
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property • ACCESS Newswire • 04/15/2026 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 05:07:36 PM
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval • ACCESS Newswire • 04/07/2026 01:10:00 PM
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
- Lexaria Bioscience Corp. Provides Strategic Update • ACCESS Newswire • 10/09/2025 01:20:00 PM
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/29/2025 08:30:00 PM
